ELTXElicio Therapeutics
About Elicio Therapeutics
Elicio Therapeutics (NASDAQ:ELTX) is dedicated to advancing vaccine and immunotherapy technologies for treating cancer and other serious diseases. Operating from its base, Elicio focuses on developing a robust pipeline of products aimed at eliciting potent immune responses targeted specifically at disease sites. Their projects integrate cutting-edge research in amphiphile technology to design therapies that precisely activate the immune system, promising a new era of precision medicine. Elicio's objectives are centered on transforming the landscape of cancer treatment, making therapies more effective and accessible to patients globally. Through continuous innovation and strategic collaboration, Elicio strives to achieve breakthroughs that will redefine standards of care in immuno-oncology.
What is ELTX known for?
Snapshot
Public US
Ownership
2011
Year founded
32
Employees
Boston, United States
Head office
1 of 5
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Boston, US
Products and/or services of Elicio Therapeutics
- Immunotherapy Research & Development: Elicio focuses on researching and developing ELI-002, a vaccine targeting mKRAS mutations in cancer, and potentially other similar therapies in the future.
- Clinical Trial Management: Elicio conducts and manages clinical trials to test the safety and efficacy of their drug candidates like ELI-002.
- Collaboration with Research Institutions: Elicio might collaborate with research institutions for further development of their therapies or technologies.
- Data Analysis & Reporting: They analyze data from clinical trials and report the findings to regulatory agencies and the scientific community.
- Investor Relations & Communication: Elicio communicates with investors regarding their progress and developments.
- Technology Development: They work on developing and improving their Elicio AMP Technology platform for creating new immunotherapies.
Elicio Therapeutics executive team
- Mr. Robert T. ConnellyCEO, President & Director
- Dr. Allen Richard Nissenson F.A.S.N., FACP, M.D.Founder & Independent Director
- Dr. Peter DeMuth Ph.D.Chief Scientific Officer
- Dr. Christopher M. Haqq M.D., Ph.D.Executive VP, Head of Research & Development and Chief Medical Officer
- Dr. Darrell J. Irvine Ph.D.Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board
- Dr. Preetam Shah M.B.A., Ph.D.Chief Strategy & Financial Officer and Treasurer
- Mr. Marc J. Wolfgang M.S.Chief Technology Officer
- Ms. Megan C. FiloonGeneral Counsel, Secretary & Compliance Officer
- Ms. Esther WelkowskySenior Vice President of Clinical Development
- Ms. Joy SeymourVP & Head of Regulatory Affairs